Comparison of dual drug-eluting Cilotax stent and @entity1311 -eluting Taxus Liberte stent in native XXXX .

@entity1 @entity583 @entity75 @entity1311 @entity1924 @entity453 @entity715 @entity204
Cilotax stent is a new type of drug-eluting stent (DES) designed to increase the antirestenotic performance of the @entity1311 -eluting stent and decrease the risk of stent @entity715 by the incorporation of @entity1924 . Therefore, we investigated the safety and efficacy of Cilotax dual DESs and compared their performance to that of @entity1311 -eluting Taxus Liberte. @entity1 undergoing percutaneous coronary intervention for de novo @entity453 at 2 centers in Korea were randomized to receive Cilotax (n = 55) or Taxus Liberte (n = 56) stents. The primary end point was in-segment late loss at 8 months. The 2 groups had similar baseline characteristics. Cilotax stent was not inferior to Taxus Liberte stent as determined by in-segment late loss (0.28    0.30 vs 0.42    0.45 mm, difference -0.14, 95% confidence interval -0.27 to -0.01, 1-sided p = 0.028 for noninferiority). In-stent late loss was significantly lower in the Cilotax than in the Taxus Liberte group (0.22    0.31 vs 0.50    0.55 mm, p = 0.002). Although in-segment restenosis rate did not differ significantly between the 2 groups (3.8% vs 10.9%, respectively, p = 0.271), in-stent restenosis rate was significantly lower in the Cilotax stent group (0% vs 10.9%, p = 0.027). There was no stent @entity715 at 8 months in either group. Rates of @entity204 , @entity583 , and any @entity75 revascularization at 8 months were 0%, 0%, and 1.9%, respectively, in the Cilotax group and 1.8%, 0% and 3.6%, respectively, in the Taxus Liberte group. In conclusion, the Cilotax stent was safe and effective in decreasing late loss, indicating that this stent represents a promising new type of DES system.
